Eileen M. Handberg, PhD, ARNP, FACC

Eileen Handberg

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Bristol-Myers Squibb Company (MODEST), Sanofie Pasteur(MODEST) RESEARCH/RESEARCH GRANTS: PCORI(SIGNIFICANT), Aastrom Biosciences(SIGNIFICANT), Amorcyte, Inc(SIGNIFICANT), Biocardia, Inc(SIGNIFICANT), Brigham and Women's Hospital(SIGNIFICANT), Capricor(SIGNIFICANT), Cytori Therapeutics, Inc(SIGNIFICANT), Direct Flow Medical(SIGNIFICANT), Duke Clinical Rsearch Institute(SIGNIFICANT), Medtronic(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), Mesoblast Inc(SIGNIFICANT), National Institutes of Health(SIGNIFICANT), National Institutes of Health through Brigham and Women's Health(SIGNIFICANT), National Institutes of Health through University of Texas(SIGNIFICANT), National Institutes of Health through University of Rochester(SIGNIFICANT), Sanofi Aventis(SIGNIFICANT), Everyfit Inc(SIGNIFICANT), Department of Defense(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Amgen(MODEST), Ionis(MODEST), Relypsa(MODEST), AstraZeneca(MODEST), Boerhinger Ingleheim(MODEST), Daiichi Sankyo(MODEST), Gilead Sciences, Inc. (MODEST)

View Full Disclosure